c-Kit-Inhibitors-Modulators-MCE

1、 HYPERLINK https:/www.MedChemE/Targets/c-Kit.html c-KitSCFR; CD117c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117)is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in

2、 the bone marrow. c-Kit is acytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptormay be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kitbinds to

3、 stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates andactivates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival,proliferation, and differentiation.www.M

4、edChemE 1 HYPERLINK https:/www.MedChemE/Targets/c-Kit.html c-Kit HYPERLINK https:/www.MedChemE/Targets/c-Kit.html HYPERLINK https:/www.MedChemE/Targets/c-Kit.html Inhibitors HYPERLINK https:/www.MedChemE/AC710.html AC710Cat. No.: HY-13493 HYPERLINK https:/www.MedChemE/amuvatinib.html Amuvatinib(MP47

5、0; HPK 56) Cat. No.: HY-10206AC710 is a potent PDGFR inhibitor with K s ofd0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT,PDGFR and PDGFR, respectively.Amuvatinib (MP470) is an orally bioavailablemulti-targeted tyrosine kinase inhibitor withpotent activity against mutant c-Kit, PDGFR, Flt3,c-Met and

6、 c-Ret.Purity: 99.89%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 98.07%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/Amuvatinib_hydrochloride.html Amuvatinib HYPERLINK https:/www.MedChemE/Amuvatinib_hydr

7、ochloride.html HYPERLINK https:/www.MedChemE/Amuvatinib_hydrochloride.html hydrochloride(MP470 hydrochloride; HPK 56 hydrochloride) Cat. No.: HY-10206A HYPERLINK https:/www.MedChemE/AST-487.html AST HYPERLINK https:/www.MedChemE/AST-487.html HYPERLINK https:/www.MedChemE/AST-487.html 487(NVP-AST 487

8、) Cat. No.: HY-15002Amuvatinib hydrochloride (MP470 hydrochloride) isan orally bioavailable multi-targeted tyrosinekinase inhibitor with potent activity againstmutant c-Kit, PDGFR, Flt3, c-Met and c-Ret.AST 487 is a RET kinase inhibitor with IC of50880 nM, inhibits RET autophosphorylation andactivat

9、ion of downstream effectors, also inhibitsFlt-3 with IC of 520 nM.50Purity: 98%Clinical Data: Phase 2Size: 1 mg, 5 mgPurity: 99.20%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/BLU-285.html Avapritinib(BLU-285) Cat. No.: HY-101561 HY

10、PERLINK https:/www.MedChemE/AZD2932.html AZD2932Cat. No.: HY-18179Avapritinib (BLU-285) is a highly potent,selective, and orally active KIT and PDGFRAactivation loop mutant kinases inhibitor withIC50s of 0.27 and 0.24 nM for KIT D816V andPDGFRA D842V, respectively.AZD2932 is a potent and multi-targe

11、ted kinaseinhibitor VEGFR2, PDGF, Flt-3 and c-Kit withIC s of 8, 4, 7 and 9 nM in cell assay,50respectively.Purity: 99.94%Clinical Data: LaunchedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 96.11%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK http

12、s:/www.MedChemE/AZD3229.html AZD3229 HYPERLINK https:/www.MedChemE/AZD3229.html HYPERLINK https:/www.MedChemE/AZD3229_Tosylate.html AZD3229 HYPERLINK https:/www.MedChemE/AZD3229_Tosylate.html HYPERLINK https:/www.MedChemE/AZD3229_Tosylate.html TosylateCat. No.: HY-112802 Cat. No.: HY-112802AAZD3229

13、is a potent pan-KIT mutant inhibitor forthe treatment of gastrointestinal stromal tumors.AZD3229 Tosylate is a potent pan-KIT mutantinhibitor for the treatment of gastrointestinalstromal tumors.Purity: 99.83%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98.54%C

14、linical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/bezuclastinib.html Bezuclastinib HYPERLINK https:/www.MedChemE/bezuclastinib.html HYPERLINK https:/www.MedChemE/c-Kit-IN-1.html c-Kit-IN-1(CGT9486; PLX 9486) Cat. No.: HY-145557Cat. No.: HY-152

15、40Bezuclastinib (CGT9486; PLX 9486) is a potentinhibitor of c-kit and c-kit D816V(0.0001IC 1 M; extracted from patent50WO2014100620 A2, compound P-2007). Bezuclastinibis a tyrosine kinase inhibitor.c-Kit-IN-1 is a potent inhibitor of c-Kit andc-Met with IC s of 98%Clinical Data: No Development Repor

16、tedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98.72%Clinical Data: Phase 1Size: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/c-kit-in-2.html c-Kit-IN-2 HYPERLINK https:/www.MedChemE/c-kit-in-2.html HYPERLINK

17、 https:/www.MedChemE/c-kit-in-5-1.html c-Kit-IN-5-1Cat. No.: HY-128602 Cat. No.: HY-18302c-Kit-IN-2 is a c-KIT inhibitor with an IC of 8250nM, shows superior antiproliferative activitiesagainst all the three GIST cell lines, GIST882,GIST430, and GIST48, with GI s of 3, 1, and 2 nM,50respectively.c-K

18、it-IN-5 is potent inhibitor of c-Kit, with IC s50of 22 nM and 16 nM in kinase assay and cell assay,respectively. c-Kit-IN-5 shows more than 200-foldselectivity for c-Kit over KDR, p38, Lck, and Src.c-Kit-IN-5 also exhibits desirable pharmacokineticproperties.Purity: 98%Clinical Data: No Development

19、ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/Cabozantinib.html Cabozantinib(XL184; BMS-907351) Cat. No.: HY-13016 HYPERLINK https:/www.MedChemE/cabozantinib-d4.html Cabozantinib-d4(XL184-d4; BMS-907351-d4) Cat. No.: HY-13016S

20、1Cabozantinib is a potent multiple receptortyrosine kinases (RTKs) inhibitor that inhibitsVEGFR2, c-Met, Kit, Axl and Flt3 with IC s of500.035, 1.3, 4.6, 7 and 11.3 nM, respectively.Cabozantinib-d4 is deuterium labeled Cabozantinib.Cabozantinib is a potent multiple receptortyrosine kinases (RTKs) in

21、hibitor that inhibitsVEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.Purity: 99.96%Clinical Data: LaunchedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/cab

22、ozantinib-d6.html Cabozantinib-d6Cat. No.: HY-13016S HYPERLINK https:/www.MedChemE/chiauranib.html Chiauranib(CS2164) Cat. No.: HY-124526Cabozantinib-d6 (XL184-d6) is the deuteriumlabeled Cabozantinib. Cabozantinib is a potentmultiple receptor tyrosine kinases (RTKs)inhibitor that inhibits VEGFR2, c

23、-Met, Kit, Axland Flt3 with IC s of 0.035, 1.3, 4.6, 7 and 11.350nM, respectively.Chiauranib (CS2164) is an orally activemulti-target inhibitor against tumor angiogenesis.Purity: 98.14%Clinical Data: No Development ReportedSize: 2.5 mg, 1 mg, 5 mg, 10 mgPurity: 99.28%Clinical Data: No Development Re

24、portedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/chmfl-abl-kit-155.html CHMFL-ABL/KIT-155 HYPERLINK https:/www.MedChemE/chmfl-abl-kit-155.html HYPERLINK https:/www.MedChemE/chmfl-kit-033.html CHMFL-KIT-033(CHMFL-ABL-KIT-155) Cat. No.: HY-101034Cat. No.: HY-1285

25、89CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34)is a highly potent and orally active type IIABL/c-KIT dual kinase inhibitor (IC s of 46 nM and5075 nM, respectively), and it also presentssignificant inhibitory activities to BLK (IC =8150nM), CSF1R (IC =227 nM), DDR1 ( =116 nM),Purity: 98%50 IC50C

26、linical Data: No Development ReportedSize: 1 mg, 5 mgCHMFL-KIT-033 is a potent and selective inhibitorof c-KIT T670I mutant for gastrointestinalstromal tumors (GISTs), with an IC of 0.045 M.50Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/Dovitinib.ht

27、ml Dovitinib HYPERLINK https:/www.MedChemE/Dovitinib.html HYPERLINK https:/www.MedChemE/Dovitinib-lactate.html Dovitinib HYPERLINK https:/www.MedChemE/Dovitinib-lactate.html HYPERLINK https:/www.MedChemE/Dovitinib-lactate.html lactate(CHIR-258; TKI258) Cat. No.: HY-50905 (CHIR-258 lactate; TKI-258 l

28、actate) Cat. No.: HY-10207Dovitinib (CHIR-258) is an orally active, potentmulti-targeted tyrosine kinase (RTK) inhibitorwith IC s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM50for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3,VEGFR1/VEGFR2/VEGFR3 and PDGFR/PDGFR,respectively.Dovitinib lactate (TKI258 lactate) is amulti-

29、targeted tyrosine kinase inhibitor withIC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3,c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFR/,respectively.Purity: 99.94%Clinical Data: Phase 3Size: 10 mM 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mgPurity: 99.62%Clinical Data: Phase 3Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg

30、, 100 mg, 200 mgwww.MedChemE 3 HYPERLINK https:/www.MedChemE/dovitinib-lactate-hydrate.html Dovitinib HYPERLINK https:/www.MedChemE/dovitinib-lactate-hydrate.html HYPERLINK https:/www.MedChemE/dovitinib-lactate-hydrate.html lactate HYPERLINK https:/www.MedChemE/dovitinib-lactate-hydrate.html HYPERLI

31、NK https:/www.MedChemE/dovitinib-lactate-hydrate.html hydrate(TKI258 lactate hydrate; CHIR-258 lactate hydrate) Cat. No.: HY-B0062 HYPERLINK https:/www.MedChemE/dovitinib-d8.html Dovitinib-D8Cat. No.: HY-50905SDovitinib lactate hydrate (TKI258 lactate hydrate)is a multi-targeted tyrosine kinase inhi

32、bitor withIC s of 1, 2, 8/9, 10/13/8, 27/210 nM for ,50 FLT3c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFR/,respectively.Dovitinib-D8 (CHIR-258-D8) is the deuteriumlabeled Dovitinib. Dovitinib (CHIR-258) is amulti-targeted tyrosine kinase inhibitor withIC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3,c-Kit, FG

33、FR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 andPDGFR/PDGFR, respectively.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/Flumatinib.html Flumatinib(HHGV678) Cat. No.: HY-13904 HYPERLINK https:/www.Me

34、dChemE/flumatinib-mesylate.html Flumatinib HYPERLINK https:/www.MedChemE/flumatinib-mesylate.html HYPERLINK https:/www.MedChemE/flumatinib-mesylate.html mesylate(HHGV678 mesylate) Cat. No.: HY-13905Flumatinib (HHGV678) is an orally available,selective inhibitor of Bcr-Abl. Flumatinib inhibitsc-Abl,

35、PDGFR and c-Kit with IC s of 1.2 nM, 307.650nM and 665.5 nM, respectively.Flumatinib mesylate (HHGV678 mesylate) is anorally available, selective inhibitor of Bcr-Abl.Flumatinib mesylate inhibits c-Abl, PDGFR andc-Kit with IC s of 1.2 nM, 307.6 nM and 665.5 nM,50respectively.Purity: 99.94%Clinical D

36、ata: Phase 3Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mgPurity: 99.97%Clinical Data: Phase 4Size: 10 mM 1 mL, 500 mg HYPERLINK https:/www.MedChemE/flumatinib-d3.html Flumatinib-d3(HHGV678-d3) Cat. No.: HY-13904S HYPERLINK https:/www.MedChemE/hg-7-85-01.html HG-7-85-01Cat. No.: HY-15814Flumatinib-d3 is deute

37、rium labeled Flumatinib.Flumatinib (HHGV678) is an orally available,selective inhibitor of Bcr-Abl. Flumatinibinhibits c-Abl, PDGFR and c-Kit with IC50s of 1.2nM, 307.6 nM and 665.5 nM, respectively.HG-7-85-01 is a type II ATP competitive inhibitorof wild-type and gatekeeper mutations forms ofBcr-Ab

38、l, PDGFR, Kit, and Src kinases.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/ihmt-trk-284.html IHMT-TRK-284 HYPERLINK https:/www.MedChemE/ihmt-trk-284.html HYPERLINK https:/www.MedChemE

39、/Imatinib.html ImatinibCat. No.: HY-146697(STI571; CGP-57148B) Cat. No.: HY-15463IHMT-TRK-284 (Compound 34) is a potent, orallyactive type II TRK kinase inhibitor with IC50values of 10.5, 0.7, and 2.6 nM to TRKA, B, andC respectively. IHMT-TRK-284 displays greatselectivity profile in the kinome and

40、good in vivoantitumor efficacies.Imatinib (STI571) is an orally bioavailabletyrosine kinases inhibitor that selectivelyinhibits BCR/ABL, v-Abl, PDGFR and c-kit kinaseactivity.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.54%Clinical Data: LaunchedSize: 10 mM 1 mL, 200 m

41、g, 500 mg, 1 g, 5 g HYPERLINK https:/www.MedChemE/imatinib-d4.html Imatinib HYPERLINK https:/www.MedChemE/imatinib-d4.html HYPERLINK https:/www.MedChemE/imatinib-d4.html D4 HYPERLINK https:/www.MedChemE/imatinib-d4.html HYPERLINK https:/www.MedChemE/Imatinib-Mesylate.html Imatinib HYPERLINK https:/w

42、ww.MedChemE/Imatinib-Mesylate.html HYPERLINK https:/www.MedChemE/Imatinib-Mesylate.html Mesylate(STI571 D4; CGP-57148B D4) Cat. No.: HY-15463S1 (STI571 Mesylate; CGP-57148B Mesylate) Cat. No.: HY-50946Imatinib D4 (STI571 D4) is a deuterium labeledImatinib (STI571). Imatinib is an orallybioavailable

43、tyrosine kinases inhibitor thatselectively inhibits BCR/ABL, v-Abl, PDGFR andc-kit kinase activity.Imatinib Mesylate (STI571 Mesylate) is a tyrosinekinases inhibitor that inhibits c-Kit, Bcr-Abl, andPDGFR (IC =100 nM) tyrosine kinases.50Purity: 99.0%Clinical Data: No Development ReportedSize: 1 mg,

44、5 mgPurity: 99.91%Clinical Data: LaunchedSize: 10 mM 1 mL, 200 mg, 500 mg, 1 g, 5 g4 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/imatinib-d8.html Imatinib-d8(STI571-d8; CGP-57148B-d8) Cat. No.: HY-15463S HYPERLINK https:/www.MedChemE/ISCK03.html ISCK03Cat.

45、No.: HY-101443Imatinib D8 (STI571 D8) is a deuterium labeledImatinib (STI571). Imatinib is an orallybioavailable tyrosine kinases inhibitor thatselectively inhibits BCR/ABL, v-Abl, PDGFR andc-kit kinase activity.ISCK03 is a specific SCF/c-Kit inhibitor.Purity: 98%Clinical Data: No Development Report

46、edSize: 5 mgPurity: 99.50%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/jnj-38158471.html JNJ-38158471 HYPERLINK https:/www.MedChemE/jnj-38158471.html HYPERLINK https:/www.MedChemE/kg5.html KG5Cat. No.: HY-18317 Cat. No.: HY-1

47、5198JNJ-38158471 is a well tolerated, orallyavailable, highly selective VEGFR-2 inhibitor,with an IC of 40 nM. JNJ-38158471 also inhibits50Ret and Kit with IC s of 180 and 500 nM,50respectively.KG5 is an orally active dual PDGFR and B-Rafallosteric inhibitor. KG5 also inhibits Flt3, KITand c-Raf. KG

48、5 has anticancer, antiangiogenicactivities.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/Ki20227.html Ki20227Cat. No.: HY-10408 HYPERLINK https:/www.MedChemE/lenv

49、atinib.html Lenvatinib(E7080) Cat. No.: HY-10981Ki20227 is an orally active and highly selectivec-Fms tyrosine kinase (CSF1R) inhibitor withIC s of 2 nM, 12 nM, 451 and 217 nM for CSF1R,50VEGFR2 (vascular endothelial growth factorreceptor-2), c-Kit (stem cell factor receptor) andPDGFR (platelet-deri

50、ved growth factorLenvatinib (E7080) is an oral, multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3,FGFR1-4, PDGFR, KIT, and RET, shows potentantitumor activities.Purity: 99.17%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 2 mg, 5 mg, 10 mg, 50 mgPurity: 99.87%Clinical Data: Lau

51、nchedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/lenvatinib-mesylate.html Lenvatinib HYPERLINK https:/www.MedChemE/lenvatinib-mesylate.html HYPERLINK https:/www.MedChemE/lenvatinib-mesylate.html mesylate HYPERLINK https:/www.MedChemE/lenvatinib-mesylate.html HYPERLINK

52、https:/www.MedChemE/lenvatinib-d4.html Lenvatinib-d4(E7080 mesylate) Cat. No.: HY-10981A (E7080-d4) Cat. No.: HY-10981SLenvatinib mesylate (E7080 mesylate), an oral,multi-targeted tyrosine kinase inhibitor thatinhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, andRET, shows potent antitumor activities.Lenvatin

53、ib-d4 (E7080-d4) is the deuterium labeledLenvatinib. Lenvatinib (E7080) is an oral,multi-targeted tyrosine kinase inhibitor thatinhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, andRET, shows potent antitumor activities.Purity: 99.86%Clinical Data: LaunchedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 9

54、8%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/lenvatinib-d5.html Lenvatinib-d5 HYPERLINK https:/www.MedChemE/lenvatinib-d5.html HYPERLINK https:/www.MedChemE/linifanib.html Linifanib(E7080-d5) Cat. No.: HY-10981S1 (ABT-869; AL-39324) Cat. No.: HY-50751Lenvati

55、nib-d5 (E7080-d5) is the deuterium labeledLenvatinib. Lenvatinib (E7080) is an oral,multi-targeted tyrosine kinase inhibitor thatinhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, andRET, shows potent antitumor activities.Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of VEGFR and PDGF

56、R familywith IC s of 4, 3, 66, and 4 nM for KDR, FLT1,50PDGFR, and FLT3, respectively. Linifanib showsprominent antitumor activity.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.72%Clinical Data: Phase 3Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mgwww.MedChemE 5 H

57、YPERLINK https:/www.MedChemE/m4205.html M4205Cat. No.: HY-132166 HYPERLINK https:/www.MedChemE/Masitinib.html Masitinib(AB1010) Cat. No.: HY-10209M4205 is a c-KIT inhibitor, with an IC of 10 nM50for c-KIT V654A. M4205 has high activity on c-KITmutations in exon 11, 13, 17.Masitinib (AB1010) is a pot

58、ent, orallybioavailable, and selective inhibitor of c-Kit(IC =200 nM for human recombinant c-Kit). It also50inhibits PDGFR/ (IC s=540/800 nM), ( =510 nM for LynB), Lck, and, to a lesser extent,50 Lyn IC50FGFR3 and FAK.Purity: 99.47%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 m

59、g, 100 mgPurity: 99.98%Clinical Data: Phase 3Size: 10 mM 1 mL, 10 mg, 50 mg, 100 mg, 200 mg HYPERLINK https:/www.MedChemE/masitinib-mesylate.html Masitinib HYPERLINK https:/www.MedChemE/masitinib-mesylate.html HYPERLINK https:/www.MedChemE/masitinib-mesylate.html mesylate(AB-1010 mesylate) Cat. No.:

60、 HY-10209A HYPERLINK https:/www.MedChemE/Motesanib.html Motesanib(AMG 706) Cat. No.: HY-10228Masitinib mesylate (AB-1010 mesylate) is a potent,orally bioavailable, and selective inhibitor ofc-Kit (IC =200 nM for human recombinant c-Kit). It50also inhibits PDGFR/ (IC s=540/800 nM),50 Lyn(IC = 510 nM